Takeda Pharmaceutical Co Stock Performance
| TAK Stock | USD 18.66 0.12 0.65% |
On a scale of 0 to 100, Takeda Pharmaceutical holds a performance score of 30. The entity has a beta of 0.26, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Takeda Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Takeda Pharmaceutical is expected to be smaller as well. Please check Takeda Pharmaceutical's maximum drawdown, accumulation distribution, relative strength index, as well as the relationship between the semi variance and day typical price , to make a quick decision on whether Takeda Pharmaceutical's existing price patterns will revert.
Risk-Adjusted Performance
High
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Takeda Pharmaceutical Co are ranked lower than 30 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Takeda Pharmaceutical disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
Five Day Return 2.3 | Year To Date Return 19.46 | Ten Year Return (22.73) | All Time Return (31.77) |
Forward Dividend Yield 0.0354 | Payout Ratio | Forward Dividend Rate 0.66 | Dividend Date 2025-12-11 | Ex Dividend Date 2025-09-30 |
| Takeda Pharmaceutical dividend paid on 11th of December 2025 | 12/11/2025 |
1 | KROS Stock Surges 85.6 percent in a Year More Upside Potential in 2026 | 01/15/2026 |
2 | Takeda Pharmaceutical Updates FY 2025 Earnings Guidance | 01/30/2026 |
3 | Takeda Q2 2025 Earnings Call Transcript | 02/05/2026 |
4 | Takeda deepens AI drug discovery push with 1.7 billion Iambic deal | 02/09/2026 |
5 | U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takedas Oveporexton as a Potential First-in-Class Therapy for Narc... | 02/10/2026 |
6 | Middle-class Americans are selling their plasma to make ends meet | 02/12/2026 |
7 | How FDA Priority Review For Narcolepsy Drug Oveporexton At Takeda Pharmaceutical Has Changed Its Investment Story | 02/18/2026 |
8 | Positive Phase 3 Data Demonstrate Potential for ENTYVIO to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis | 02/19/2026 |
| Begin Period Cash Flow | 457.8 B | |
| Total Cashflows From Investing Activities | -367.1 B |
Takeda Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 1,450 in Takeda Pharmaceutical Co on November 25, 2025 and sell it today you would earn a total of 416.00 from holding Takeda Pharmaceutical Co or generate 28.69% return on investment over 90 days. Takeda Pharmaceutical Co is generating 0.4274% of daily returns assuming volatility of 1.1254% on return distribution over 90 days investment horizon. In other words, 10% of stocks are less volatile than Takeda, and above 92% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Takeda Pharmaceutical Target Price Odds to finish over Current Price
The tendency of Takeda Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 18.66 | 90 days | 18.66 | roughly 2.8 |
Based on a normal probability distribution, the odds of Takeda Pharmaceutical to move above the current price in 90 days from now is roughly 2.8 (This Takeda Pharmaceutical Co probability density function shows the probability of Takeda Stock to fall within a particular range of prices over 90 days) .
Takeda Pharmaceutical Price Density |
| Price |
Predictive Modules for Takeda Pharmaceutical
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Takeda Pharmaceutical. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Takeda Pharmaceutical Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Takeda Pharmaceutical is not an exception. The market had few large corrections towards the Takeda Pharmaceutical's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Takeda Pharmaceutical Co, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Takeda Pharmaceutical within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.38 | |
β | Beta against Dow Jones | 0.26 | |
σ | Overall volatility | 1.46 | |
Ir | Information ratio | 0.29 |
Takeda Pharmaceutical Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Takeda Pharmaceutical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Takeda Pharmaceutical can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Takeda Pharmaceutical has a strong financial position based on the latest SEC filings | |
| Latest headline from finance.yahoo.com: Positive Phase 3 Data Demonstrate Potential for ENTYVIO to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis |
Takeda Pharmaceutical Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Takeda Stock often depends not only on the future outlook of the current and potential Takeda Pharmaceutical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Takeda Pharmaceutical's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.2 B | |
| Cash And Short Term Investments | 405.6 B |
Takeda Pharmaceutical Fundamentals Growth
Takeda Stock prices reflect investors' perceptions of the future prospects and financial health of Takeda Pharmaceutical, and Takeda Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Takeda Stock performance.
| Return On Equity | 0.015 | ||||
| Return On Asset | 0.0247 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 84.78 B | ||||
| Shares Outstanding | 3.16 B | ||||
| Price To Earning | 27.57 X | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 0.01 X | ||||
| Revenue | 4.58 T | ||||
| Gross Profit | 2.93 T | ||||
| EBITDA | 1.21 T | ||||
| Net Income | 107.93 B | ||||
| Cash And Equivalents | 233.74 B | ||||
| Cash Per Share | 208.91 X | ||||
| Total Debt | 4.52 T | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 1.18 X | ||||
| Book Value Per Share | 31.21 X | ||||
| Cash Flow From Operations | 1.06 T | ||||
| Earnings Per Share | 0.23 X | ||||
| Market Capitalization | 58.95 B | ||||
| Total Asset | 14.25 T | ||||
| Retained Earnings | 1.19 T | ||||
| Working Capital | 14.67 B | ||||
About Takeda Pharmaceutical Performance
By examining Takeda Pharmaceutical's fundamental ratios, stakeholders can obtain critical insights into Takeda Pharmaceutical's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Takeda Pharmaceutical is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 188.07 | 130.94 | |
| Return On Tangible Assets | 0.02 | 0.02 | |
| Return On Capital Employed | 0.06 | 0.11 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.02 | 0.02 |
Things to note about Takeda Pharmaceutical performance evaluation
Checking the ongoing alerts about Takeda Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Takeda Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Takeda Pharmaceutical has a strong financial position based on the latest SEC filings | |
| Latest headline from finance.yahoo.com: Positive Phase 3 Data Demonstrate Potential for ENTYVIO to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis |
- Analyzing Takeda Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Takeda Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Takeda Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Takeda Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Takeda Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Takeda Pharmaceutical's stock. These opinions can provide insight into Takeda Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Takeda Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 3.302 | Dividend Share 198 | Earnings Share 0.23 | Revenue Per Share | Quarterly Revenue Growth 0.042 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Takeda Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.